Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases. The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.
前收盤價
US$14.99
−US$1.01 · -6.31%
盤中時間採用ET。市場資料可能有所延遲。
Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases. The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.
日內區間
目前US$14.99
52週區間
目前US$14.99
盤中時間採用ET。市場資料可能有所延遲。
Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases. The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.
日內區間
目前US$14.99
52週區間
目前US$14.99
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
